Science Current Events | Science News | Brightsurf.com
 

Combining therapies can improve survival for early-stage breast cancer patients

April 04, 2007

Patients with early-stage breast cancer who are treated with both chemotherapy and tamoxifen have a higher survival rate than patients who receive only tamoxifen. But a combination of tamoxifen and ovarian suppression—treatment to stop the ovaries from functioning—did not show any additional benefits, according to two randomized clinical trials published in the April 4 Journal of the National Cancer Institute.

Survival rates improve for patients with early-stage breast cancer who receive a single method of treatment—either tamoxifen, ovarian suppression, or chemotherapy. Two international studies by the Adjuvant Breast Cancer Trials Collaborative Group were designed to test whether combining these treatments would provide additional benefits.

Judith Bliss of The Institute of Cancer Research in Sutton, England, and colleagues conducted two randomized controlled phase III clinical trials of 3,854 women with early-stage breast cancer, all of whom were treated with tamoxifen for five years. In the first trial, nearly half of the 2,144 premenopausal women were randomly assigned to receive ovarian suppression, and the other half did not. Some also received chemotherapy. In the second trial, 1,991 patients were randomly assigned to receive chemotherapy, and the other half were not. Some premenopausal women also had ovarian suppression.

The researchers found that chemotherapy treatment resulted in a modest yet sustained improvement in both relapse-free and overall survival. These improvements were especially strong in women younger than 50 years and in premenopausal women who did not receive ovarian suppression.

They also found that neither relapse-free survival nor overall survival was affected by the addition of ovarian suppression. However, the results indicate a possible benefit of ovarian suppression when given along side tamoxifen for a small group of women younger than 40 years who have ER-positive tumors (tumors that need estrogen to grow), especially when they are not receiving chemotherapy. The researchers called for further research into this group of breast cancer patients.

"Relapse-free survival benefits emerged early and were maintained, whereas overall survival benefits did not emerge for at least 5 years, reinforcing the need for long-term follow-up in chemotherapy trials," the authors write. The trials add "to the limited data available on the effects of combining long-term tamoxifen, chemotherapy, and ovarian ablation of suppression."

In an accompanying editorial, Kathleen Pritchard, M.D., of Toronto Sunnybrook Regional Cancer Centre, describes how the trial could have found more interesting results if there had been more data on patients' ER status. "Most of all, however, these studies stress the importance of establishing processes to ensure the availability of archived tumor specimens for all randomized adjuvant trials. The era in which such large important trials should be carried out without the archived correlational tumor samples is over."

Journal of the National Cancer Institute


Related Tamoxifen Current Events and Tamoxifen News Articles


Recommendation to omit radiation therapy after lumpectomy is not frequently implemented
Nearly two thirds of U.S. women age 70 or older with stage I breast cancer1 who undergo lumpectomy and are eligible to safely omit subsequent radiation therapy (RT) according to national cancer guidelines still receive this treatment, according to new study results.

From tamoxifen to dendrogenin A: Discovery of a mammalian tumor suppressor metabolite
Researchers from the Cancer Research Center of Toulouse have conducted the first comprehensive review on dendrogenin A (DDA).

Why does tamoxifen work better in some women?
The anti-hormone therapy tamoxifen can reduce breast cancer recurrence by about half in women with hormone-sensitive breast cancer. But it works better in some women than others. Researchers are not sure why.

No significant differences in recurrence rates among women with DCIS taking anastrozole or tamoxifen
Postmenopausal women with ductal carcinoma in situ (DCIS) had similar outcomes with disease recurrence whether they took tamoxifen or the aromatase inhibitor anastrozole for five years after surgery, but women in the two groups had different side effects.

Five out of six women at higher risk reject drugs to prevent breast cancer
Cancer Research UK scientists have found that five in six women with increased risk of breast cancer turn down drugs likely to prevent the disease, according to research published in Annals of Oncology.

Aspirin use does not improve outcomes for cancer patients, but may lower breast density
Whether aspirin may help prevent or reduce the risk of breast cancer remains a hotly debated research question.

Denosumab improves disease-free survival for postmenopausal patients w HR+ breast cancer
Adding denosumab to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal patients with early-stage, hormone receptor (HR)-positive breast cancer, according to results from the phase III ABCSG-18 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.

Taking antidepressants with cancer drug does not increase breast-cancer recurrence
A large study of patients with breast cancer who took the anti-cancer drug tamoxifen while taking an antidepressant were not found to have an increased risk of recurrence. The Kaiser Permanente study was published today in The Journal of the National Cancer Institute.

No need to stop antidepressants before plastic surgery, evidence suggests
For patients undergoing plastic surgery procedures, there's no consistent evidence that taking antidepressants increases the risk of bleeding, breast cancer, or other adverse outcomes, concludes a research review in the November issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).

Study shows association between breastfeeding and reduced risk of aggressive breast cancer
A large international study shows that breastfeeding is associated with a lower risk of developing an aggressive form of breast cancer called hormone-receptor negative.
More Tamoxifen Current Events and Tamoxifen News Articles

Tamoxifen and Breast Cancer (Yale Fastback Series)

Tamoxifen and Breast Cancer (Yale Fastback Series)
by Michael W. DeGregorio (Author), Valerie J. Wiebe (Author)


A discussion of the diagnosis of breast cancer and the risks, benefits and limitations of treatment alternatives, particularly tamoxifen. This edition contains information on developments in the use of tamoxifen, especially in the results of the Breast Cancer Prevention Trial.

Tamoxifen: Pioneering Medicine in Breast Cancer (Milestones in Drug Therapy)

Tamoxifen: Pioneering Medicine in Breast Cancer (Milestones in Drug Therapy)
by Springer


Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years.This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the...

The Whole-Food Guide for Breast Cancer Survivors: A Nutritional Approach to Preventing Recurrence (The New Harbinger Whole-Body Healing Series)

The Whole-Food Guide for Breast Cancer Survivors: A Nutritional Approach to Preventing Recurrence (The New Harbinger Whole-Body Healing Series)
by Edward Bauman MEd PhD (Author), Helayne Waldman MS EdD (Author), Donald I. Abrams MD (Foreword)


If you’re a breast cancer survivor, chances are you have renewed your commitment to maintaining your good health and taking care of your body. As one of the best preventative measures known to doctors and nutritionists today, a robust, cancer-fighting diet is vital to your personal plan for breast cancer prevention.The Whole-Food Guide for Breast Cancer Survivors is an essential guide for every woman seeking to understand the effect of nutritional deficiencies and environmental factors on her overall health and wellness. Based on Edward Bauman’s groundbreaking Eating for Health model, this highly comprehensive, practical approach can help you reduce the chance of breast cancer recurrence; rebuild your immune system; and enjoy a stronger, healthier body.Reduce the chance of breast...

Tamoxifen: A Guide for Clinicians and Patients

Tamoxifen: A Guide for Clinicians and Patients
by Northwestern Univ. Medical School V. Craig Jordan (Editor)


Book is very Excellent condition. It does not have a dust jacket but the cover is like new.

Tamoxifen: Beyond the Antiestrogen

Tamoxifen: Beyond the Antiestrogen
by Birkhäuser


Tamoxifen has persisted as a widely accepted and administered drug for almost 25 years. Following the many scientific papers and books on the subject, it has remained a very intriguing substance. This, perhaps, is the reason for another monograph on Tamoxifen. It is regrettably true that overviews, even when up to date after exhaustive research - the shibboleth of our cultures -, rapidly lose relevance with the passage of time. Scientists can sometimes be pictured as deep sea divers, who plunge into the unknown in search of a hitherto unknown world. Their descent is exciting, but eventually they must come up for air and integrate their experiences with others who also had to resurface. This book intends to collect and, where possible, to collate recent, but sometimes seemingly unrelated...

Tamoxifen: Beyond the Antiestrogen

Tamoxifen: Beyond the Antiestrogen
by John A. Kellen (Author)


Tamoxifen has persisted as a widely accepted and administered drug for almost 25 years. Following the many scientific papers and books on the subject, it has remained a very intriguing substance. This, perhaps, is the reason for another monograph on Tamoxifen. It is regrettably true that overviews, even when up to date after exhaustive research - the shibboleth of our cultures -, rapidly lose relevance with the passage of time. Scientists can sometimes be pictured as deep sea divers, who plunge into the unknown in search of a hitherto unknown world. Their descent is exciting, but eventually they must come up for air and integrate their experiences with others who also had to resurface. This book intends to collect and, where possible, to collate recent, but sometimes seemingly unrelated...

The Wisdom of Menopause (Revised Edition): Creating Physical and Emotional Health During the Change

The Wisdom of Menopause (Revised Edition): Creating Physical and Emotional Health During the Change
by Christiane Northrup M.D. (Author)


Dr. Christiane Northrup’s #1 New York Times bestseller The Wisdom of Menopause has inspired more than a million women with a dramatically new vision of midlife—and will continue to do so for generations to come. As Dr. Northrup has championed, the “change” is not simply a collection of physical symptoms to be “fixed,” but a mind-body revolution that brings the greatest opportunity for growth since adolescence. The choices a woman makes now—from the quality of her relationships to the quality of her diet—have the power to secure vibrant health and well-being for the rest of her life.

Now completely revised, this groundbreaking classic draws on the current research and medical advances in women’s health, and includes
 
• a new section on sex after 50—and...

A Cancer in the Family: Take Control of Your Genetic Inheritance

A Cancer in the Family: Take Control of Your Genetic Inheritance
by Theodora Ross MD PhD (Author), Siddhartha Mukherjee (Author)


Oncologist and cancer gene hunter Theo Ross delivers the first authoritative, go-to for people facing a genetic predisposition for cancer
 
There are 13 million people with cancer in the United States, and it’s estimated that about 1.3 million of these cases are hereditary. Yet despite advanced training in cancer genetics and years of practicing medicine, Dr. Theo Ross was never certain whether the history of cancers in her family was simple bad luck or a sign that they were carriers of a cancer-causing genetic mutation. Then she was diagnosed with melanoma, and for someone with a dark complexion, melanoma made no sense. It turned out there was a genetic factor at work.
 
Using her own family’s story, the latest science of cancer genetics, and her experience as a...

Tamoxifen: New Hope in the Fight Against Breast Cancer

Tamoxifen: New Hope in the Fight Against Breast Cancer
by John F. Kessler (Author), Greg A. Annussek (Author)


On the market in the United States since 1978, tamoxifen is the most widely prescribed anti-cancer drug in the world. Recently, this powerful cancer fighter has been found to prevent breast cancer, and its use as a breast cancer preventive has been approved by the FDA. For women at high risk of breast cancer, tamoxifen provides a new option for prevention of this disease. Now, in this comprehensive, accessible guide, a medical doctor provides answers to the critical questions every woman should ask before considering preventive therapy or cancer treatment with tamoxifen.Should I consider myself at high risk of breast cancer?
Do the risks of breast cancer outweight the risks of taking tamoxifen?
How does tamoxifen compare with other prevention therapies?
What are the side effects...

Tamoxifen and Breast Cancer (Yale Fastback Series) 2 Upd Sub Edition by DeGregorio, Dr. Michael W.; Wiebe, Valerie J. published by Yale University Press

Tamoxifen and Breast Cancer (Yale Fastback Series) 2 Upd Sub Edition by DeGregorio, Dr. Michael W.; Wiebe, Valerie J. published by Yale University Press
by Yale University Press (Publisher)




© 2016 BrightSurf.com